Member Info for Moneymunch

12p plus and more Monday imho...Perfectly poised and primed!!! Gla holders.:-)

 0

They don't need to raise cash...Huw stated last month they have enough to the end of this year....and so he wouldn't likely highlight the favourable cash position if he was planning a fund raise anytime soon....and a lucrative commercial JV partner or two cold be waiting in the wings imho.

The business model is to seek non-dilutive funding to advance the pipeline towards commercial JV partnerships....and Evgen have more opportunities for a lucrative JV or two than most. Gla ;-)

Lol...spreadbetting shorting mugs, getting well and truly mugged.....ha ha ha ha ha......On and most definitely UP!!!!! ;-)))

Obviously not as high as mine.....Evgen are all set for a one way trajectory from small cap to Mid Cap....with multiple chances of lucrative commercial JV partnerships.......Watch this space.....those that are happy to sell at this current bargain low will all regret it, soon enough. Gla holders....Verry exciting times!!! ;-)

Lol scooby, good luck with that, i predict it will be something you will greatly regret in the coming weeks.....anyone betting short with Spreadex et all are going to get shafted.......ho ho ho ho ....ON and UP!!! ;-)

Relay Therapeutics Announces a Worldwide License and Collaboration Agreement with Genentech for RLY-1971

December 14, 2020

Collaboration brings together clinical stage SHP2 and KRAS G12C inhibitors

Relay Therapeutics will receive $75 million upfront and is eligible to receive an additional $25 million in near-term payments and $695 million in additional potential milestones,
plus royalties on global net product sales

https://www.globenewswire.com/news-release/2020/12/14/2144322/0/en/Relay-Therapeutics-Announces-a-Worldwide-License-and-Collaboration-Agreement-with-Genentech-for-RLY-1971.html

October 26, 2020

News briefing: AstraZeneca follows Amgen down KRAS/SHP2 combo path;

Revolution Medicines is adding AstraZeneca to its roster of clinical collaborators, lending its lead drug, RMC-4630, for a study pairing it with the pharma giant’s KRAS G12C program.

AstraZeneca will sponsor and conduct the study once its now preclinical drug is ready for human studies, an arrangement similar to the deal Revolution has with Amgen on sotorasib.

“Drug combinations are likely to be critical for defeating inherent drug resistance mechanisms exploited by RAS-addicted cancers,� CEO Mark Goldsmith said in a statement.

An allosteric SHP2 inhibitor, RMC-4630 attracted Sanofi for a partnership that involved $50 million upfront, 80% of the R&D cost, and a swath of milestones adding up to $520 million. Revolution is also working on a pipeline — from its buyout of Warp Drive Bio — of drugs that directly inhibit oncogenic RAS(ON) variants, including KRASG12C(ON) and KRASG12D(ON).

htTps://endpts.com/news-briefing-astrazeneca-follows-amgen-down-kras-shp2-combo-path-vallon-pharmaceuticals-files-for-17-million-ipo/

......................

December 21, 2020

Financing

China

Months af­ter strik­ing SHP2 deal with Ab­b­Vie, Ja­co­bio pulls in $174M+ from Hong Kong IPO

The sea­soned crew at Ja­co­bio has raised $174.1 mil­lion on its HKEX de­but, fu­elling a pipeline an­chored by two Ab­b­Vie-part­nered al­losteric SHP2 in­hibitors.

..............

AbbVie and Jacobio Announce Strategic Collaboration to Advance SHP2 Inhibitors

News provided by
AbbVie

Jun 01, 2020, 01:00 ET

Share this article

NORTH CHICAGO, Ill. and BEIJING, June 1, 2020 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, and Jacobio Pharmaceuticals, a clinical-stage pharmaceutical company, today announced a global, strategic collaboration to develop and commercialize SHP2 inhibitors, which target a key node in cancer and immune cells.

SHP2 is an important protein mediator of cellular signaling through RAS/MAP kinase pathway. Many tumors have genetic mutations, driving abnormal cancer cell growth which relies on SHP2 activity. SHP2 also plays a key role to control cytokine production and immune cell response. Therefore, inhibition of SHP2 is believed to have dual effects by potentially reducing cancer cell growth and modulating immune responses to generate anti-tumor activities. Jacobio's early clinical stage SHP2 assets, JAB-3068 and JAB-3312, are oral small molecules designed to specifically inhibit SHP2 activity.

Lol..... better to be feeling smug as opposed to feeling like a MUG....eh Superboy....ha ha ha ha ;-)

SHP2 pathway.....RED HOT Oncology target for lucrative licensing deals....here's a few recent exapample. Gla ;-)

TOKYO, Japan; 13 January, 2021

Taiho Pharmaceutical Co, Ltd., (hereinafter Taiho) announces that it and Astex Pharmaceuticals (UK), (hereinafter Astex), both Otsuka group companies, have granted an exclusive license under their joint, small-molecule drug discovery program targeting SHP2 to Merck & Co., Inc., Kenilworth, NJ, USA, known as MSD outside the United States and Canada (hereinafter MSD) through a subsidiary.

htTps://www.pharmiweb.com/press-release/2021-01-13/taiho-and-astex-extend-strategic-oncology-collaboration-with-msd-granting-exclusive-license-to-shp2-program

...................

Erasca Unveils Its First Strategy to Erase Cancer, Accelerated by Expansion of Precision Oncology Pipeline and Dosing of First Patient

Successful additions of ERAS-601 and ERAS-007, potential best-in-class inhibitors of SHP2 and ERK, respectively, enable “MAPK Clamp” approach to shut down RAS/MAPK pathway

Erasca doses first patient in FLAGSHP-1 study, Erasca’s first clinical trial
January 06, 2021 08:00 AM Eastern Standard Time

SAN DIEGO--(BUSINESS WIRE)--Erasca, a company whose mission is to erase cancer, announced the expansion of its pipeline of precision oncology therapies via two exclusive, worldwide agreements directed at targeting critical upstream and downstream nodes in the RAS/MAPK signaling cascade, one of the most frequently mutated oncogenic pathways in cancer. ERAS-601, a potential best-in-class inhibitor of the Src homology region 2 domain-containing phosphatase-2 (SHP2), was licensed from NiKang Therapeutics, Inc. ERAS-007, a potential best-in-class inhibitor of the extracellular signal-regulated kinase (ERK), the most distal node of the RAS/MAPK pathway, was acquired from ASN Product Development, Inc., a wholly owned subsidiary of Asana BioSciences, LLC.

https://www.businesswire.com/news/home/20210106005241/en/Erasca-Unveils-Its-First-Strategy-to-Erase-Cancer-Accelerated-by-Expansion-of-Precision-Oncology-Pipeline-and-Dosing-of-First-Patient

RNS Number : 5197M
Evgen Pharma PLC
22 January 2021


Evgen Pharma plc

("Evgen" or "the Company" or "the Group")



Preclinical data on a new therapeutic target for SFX-01

Lead candidate SFX-01 inhibits SHP2, a protein associated with a number of different cancer types



Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases, announces preclinical data demonstrating that SFX-01 is an inhibitor of SHP2.

SHP2 (Src homology-2 domain-containing protein tyrosine phosphatase-2) is a non-receptor protein tyrosine phosphatase that is associated with breast cancer, leukaemia, lung cancer, liver cancer, gastric cancer, laryngeal cancer, oral cancer and other cancer types.



In-vitro and in-vivo data generated by Professor Philip Eaton, Queen Mary University of London, demonstrates that SFX-01 modifies SHP2, inhibiting its phosphatase activity; this phosphatase is implicated in many aspects of cancer. SHP2 is involved in several cancer-related processes, including cancer cell invasion and metastasis, apoptosis, DNA damage, cell proliferation, cell cycle and drug resistance. SHP2 may therefore be a therapeutic target of great potential.



This exciting data provides another pathway through which SFX-01 may be a valuable anti-cancer agent in addition to its effects on the STAT3 pathway, thought to be the principal mechanism of action in metastatic breast cancer.



Further preclinical work is being conducted in cancer models and data will be announced in due course.

Dr Huw Jones, CEO of Evgen Pharma, commented: "SHP2 has been a target of some interest for a while, but to date attempts to develop an inhibitor have had limited success. We are delighted that the data generated by Professor Eaton demonstrates that SFX-01 acts on SHP2 in a novel manner and offers the potential for its use in a number of cancers with great clinical need."

Lol.....get your head out of your arse....Superboy!!! ;-)

Finncap 21/1/21

Positive data in glioma adds another string to the bow

Evgen announced that highly positive data (tumour shrinkage and significantly extended survival times) has been generated through collaborators for SFX-01 in pre-clinical models of glioma, including the more severe Grade IV glioblastoma.

Given the poor prognosis and lack of current treatment options, it is easy to see this product entering Phase Ib/IIa trial in the near-term and/or generating a pre- clinical licensing deal. We maintain our target price of 25p, which is based on an rNPV for SFX-01 in mBC only.

This excludes any value attributable to other indications, such as ARDS/COVID-19, other potential investigator-led studies, or the value of Sufloradex, which was licensed to Juvenescence for non- pharmaceutical uses.

These data potentially offer substantial incremental value to the business whilst also de-risking it further.

Newsflow:

Highly positive data for SFX-01 in pre-clinical models of glioma and glioblastoma have been generated through a collaboration with a prominent European university.

Fuller details are pending the publication in a peer-reviewed journal. However, Evgen is particularly excited with the findings and with limited additional preclinical work, has indicated that SFX-01 could be ready to enter the clinic (Phase Ib/IIa) by the year-end.

Glioma is the most common type of brain tumour, developing in glial cells (supporting cells) in the brain or spinal cord. Different types of glioma are named after the types of glial cell and include Glioblastoma, which is an aggressive type of astrocytoma (forms in astrocyte cells). Glioblastoma accounts for c.45% of cases with a median survival of 14 months and 5-year survival of c.5%.

It is an orphan disease affecting 5 per 100,000 people. We would expect SFX-01 to receive Orphan Drug Designation, Fast Track and potentially breakthrough status (in the US) as the treatment options are currently limited to surgery, radiotherapy and treatment with temozolomide.

Preclinical findings. Tumour shrinkage and significantly extended survival times were seen in standard pre-clinical models and then dosed with SFX-01, including more disease-relevant orthotopic models where glioma cells are implanted in brain tissue. SFX-01 was also found also to substantially increase the therapeutic effect of radiotherapy in these models.

Implications:

The data are sufficiently encouraging to warrant disclosure. Evgen retains all commercial rights to SFX-01 and will consider all options for further development.

It is quite conceivable that once limited additional preclinical work is completed a high-value preclinical deal could be struck, given the paucity of current treatment options and products in development for this indication.

They have enough cash until end of year according to the CEO's interview last month and their business model is to seek non-dilutive funding to advance the pipeline, and so any near term fund raise would be unlikely imho, unless for a very special material event and I really don't think that Huw would have mentioned the favourable cash position if had plans for a fund raise anytime soon .Gla :-)

Ps plenty more positive newsflow potential in the coming days and weeks....a sudden and significant re-rate at anytime.

A very bullish note indeed and also highlights the encouraging prospects of a pre-clinical licensing deal on this very hard to treat cancer with very few therapeutic options.

There's been a raft of early stage lucrative licensing deals over the last several months and weeks involving the key pathways, Nrf2, STAT3 and SHP2 and so one would hope that a Major player or two might be interested in SFX-01's properties and potential over multiple disease targets.

The Unversity of Manchester is currently carrying out further clinical work prior to the planned phase 2b patient trials for breast cancer, and so another near term potential target for a commercial JV partner, given how outstanding the phase 2 results were, and of course all eyes on SFX-01's Covid/ARDS trial, the greenlight from the DSMB will be very big news, a huge endorsement towards the validation of SFX-01's efficacy.....so much potential transformational upside from a lowly market cap...a rare opportunity imho...I can't think of many other small cap Bio's with so many strings to their bow as EVG's...Gla :-)

 Finncap's Research note courtesy of peanut on Advfn. Gla :-)

Positive data in glioma adds another string to the bow

Evgen announced that highly positive data (tumour shrinkage and significantly extended survival times) has been generated through collaborators for SFX-01 in pre-clinical models of glioma, including the more severe Grade IV glioblastoma. Given the poor prognosis and lack of current treatment options, it is easy to see this product entering Phase Ib/IIa trial in the near-term and/or generating a pre- clinical licensing deal. We maintain our target price of 25p, which is based on an rNPV for SFX-01 in mBC only. This excludes any value attributable to other indications, such as ARDS/COVID-19, other potential investigator-led studies, or the value of Sufloradex, which was licensed to Juvenescence for non- pharmaceutical uses. These data potentially offer substantial incremental value to the business whilst also de-risking it further.
?Newsflow: Highly positive data for SFX-01 in pre-clinical models of glioma and glioblastoma have been generated through a collaboration with a prominent European university. Fuller details are pending the publication in a peer-reviewed journal. However, Evgen is particularly excited with the findings and with limited additional preclinical work, has indicated that SFX-01 could be ready to enter the clinic (Phase Ib/IIa) by the year-end.
?Glioma is the most common type of brain tumour, developing in glial cells (supporting cells) in the brain or spinal cord. Different types of glioma are named after the types of glial cell and include Glioblastoma, which is an aggressive type of astrocytoma (forms in astrocyte cells). Glioblastoma accounts for c.45% of cases with a median survival of 14 months and 5-year survival of c.5%. It is an orphan disease affecting 5 per 100,000 people. We would expect SFX-01 to receive Orphan Drug Designation, Fast Track and potentially breakthrough status (in the US) as the treatment options are currently limited to surgery, radiotherapy and treatment with temozolomide.
?Preclinical findings. Tumour shrinkage and significantly extended survival times were seen in standard pre-clinical models and then dosed with SFX-01, including more disease-relevant orthotopic models where glioma cells are implanted in brain tissue. SFX-01 was also found also to substantially increase the therapeutic effect of radiotherapy in these models.
?Implications: The data are sufficiently encouraging to warrant disclosure. Evgen retains all commercial rights to SFX-01 and will consider all options for further development. It is quite conceivable that once limited additional preclinical work is completed a high-value preclinical deal could be struck, given the paucity of current treatment options and products in development for this indication.

Positive pre-clinical data for lead asset SFX-01

RNS Number : 3802M
Evgen Pharma PLC
21 January 2021

Evgen Pharma plc

("Evgen" or the "Company")

Positive pre-clinical data in Glioma for lead asset SFX-01

Evgen Pharma plc (AIM: EVG), a clinical stage drug development company, announces that its collaboration with a prominent European university has generated highly positive data for SFX-01 in pre-clinical models of glioma and glioblastoma.

Glioma is the most common form of brain tumour affecting around 5 per 100,000 people. The more severe, grade IV classification, glioblastoma, is a very serious form of brain tumour representing 45% of all cases and has a poor prognosis with median survival of around 14 months. The five-year survival of the severe grades is 5%.

The data generated for SFX-01 in standard pre-clinical models and orthotopic models (where glioma cells are implanted in brain tissue representing a more disease-relevant model) show tumour shrinkage and significantly extended survival times. SFX-01 was also found to potentiate (i.e. substantially increase) the therapeutic effect of radiotherapy in these models.

The therapeutic options for glioma are limited to surgery, radiotherapy and the one drug widely available, temozolomide. There is a clear unmet need for more treatments for use in conjunction with the current standard of care.

Dr Huw Jones, Evgen CEO, commented: "We are excited by this compelling new data in a type of cancer which has severely limited therapeutic options for the patient. The positive tolerability profile of SFX-01 makes it a viable option for use in addition to current treatments. Our plan is to expand upon these pre-clinical data in this and new collaborations, and start the process of designing an appropriate Phase II clinical trial."

Norway raises concern about Pfizer Covid-19 vaccine safety after 29 deaths
18 January 2021 (Last Updated January 18th, 2021 12:06)

Norway has raised concerns about Pfizer’s Covid-19 vaccine safety after 29 elderly people with serious underlying health conditions have died after receiving the shot.

https://www.pharmaceutical-technology.com/news/norway-concern-pfizer-vaccine/

......................

Single Covid vaccine dose in Israel 'less effective than we thought'

Surge in infections dampens optimism over country’s advanced immunisation programme

Israel’s coronavirus tsar has warned that a single dose of the Pfizer/BioNTech vaccine may be providing less protection than originally hoped, as the country reported a record 10,000 new Covid infections on Monday.

In remarks reported by Army Radio, Nachman Ash said a single dose appeared “less effective than we had thought”, and also lower than Pfizer had suggested.

By contrast, those who had received their second dose of the Pfizer vaccine had a six- to 12-fold increase in antibodies, according to data released by Sheba Medical Center in Tel Hashomer on Monday.

https://www.theguardian.com/world/2021/jan/19/single-covid-vaccine-dose-in-israel-less-effective-than-we-hoped

Prof Chalmers, Looking for additional trial sites...I'll take that as a big positive and a sign of confidence, with every chance that the recruitment process will pick up speed. Gla :-)

Follow

James D Chalmers

@ProfJDChalmers

British Lung Foundation Chair of Respiratory Research, University of Dundee. Deputy Editor of ERJ. Tweets in a personal capacity

Dundee, UKJoined July 2019

1,707 Following

3,348 Followers

Tweets

Tweets & replies

Media

Likes

James D Chalmers’s Tweets

James D Chalmers

@ProfJDChalmers

·

21m

STAR-COVID is still looking for additional trial sites. Anyone interested please e-mail or direct message me. http://star-covid19.com

Quote Tweet

James D Chalmers

@ProfJDChalmers

· 22m

Latest from the STAR-COVID trial announced today. Rapid enrolment past 50 patients randomized. Thanks @TASC_TCTU @EvgenPharma and funders @lifearc1 STAR-COVID is testing whether SFX-01 will improve outcomes in hospitalized patients with suspected COVID19 https://star-covid19.com

Show this thread

2

3

James D Chalmers

@ProfJDChalmers

·

22m

Thanks to all of the participants and their families for taking part in COVID19 research. Research is the only way we will finally beat COVID19.

Every chance of a February UPdate on DSMB's assessment on the first 100 patients. Gla ;-)

RNS Number : 0902M
Evgen Pharma PLC
19 January 2021


Evgen Pharma plc

("Evgen" or the "Company")



Update on patient recruitment in STAR-COVID 19 trial



Evgen Pharma plc (AIM: EVG), a clinical stage drug development company, announces that as of 18 January, a total of 56 patients had been recruited and randomised to the STAR trial ("SFX-01 treatment for Acute Respiratory Infections").



This Phase II/III randomised, placebo-controlled trial is sponsored by the University of Dundee and funded by the UK charity Life Arc. It will investigate whether the Company's lead asset, SFX-01, can reduce the severity, or prevent the onset of, acute respiratory distress syndrome ("ARDS") in patients with community-acquired pneumonia from any infective agent and who have been or are being tested for suspected COVID-19. Patients may therefore present with COVID-19 or other respiratory diseases.



The trial design includes an assessment of safety and futility by a Data Safety and Monitoring Board who will review unblinded data on the first 100 patients treated. An announcement will be made when this point has been reached.



SFX-01 upregulates the Nrf2 pathway which is part of the natural human defence against inflammatory and oxidative stress, such as the inflammation that occurs during a severe viral infection. Preclinical studies have shown that up-regulating the Nrf2 pathway has the potential to reduce the severity of ARDS, the progressive lung damage observed in COVID-19 and pneumonia patients, which can result in the need for invasive ventilation in an intensive care unit.



Dr Huw Jones, CEO of Evgen, commented: "We are pleased with the recruitment progress in this trial and would like to thank Professor James Chalmers and his colleagues at Dundee for their considerable efforts in a difficult clinical environment. We are greatly encouraged by recent academic papers which reinforce previous preclinical data showing the potential benefit to ARDS patients of up-regulating Nrf2 and hope that SFX-01 may be a valuable addition to the array of treatments that these seriously ill patients can receive. We look forward to further updating the market as we progress through this important trial.''

More documented research which adds weight to SFX-01's chances for Covid/ARDS..Gla ;-)

14/1/21

Helixmith announces encouraging animal model efficacy data has been published in the Journal of Ethnopharmacology for their botanical therapeutic product for respiratory diseases. A clinical trial of 100 patients diagnosed with COVID-19 to begin soon in India.

.....

Acute respiratory distress syndrome (ARDS) is a respiratory failure produced by uncontrolled excessive inflammation and oxidative stress in the lungs. The causes are diverse, including bacteria, viruses, and environmental chemicals. An acute lung injury mouse model with a high degree of pulmonary inflammation induced by a lipid polysaccharide (LPS) is one of the most frequently used animal models in ARDS studies. In the LPS-induced acute lung injury (ALI) model, lung damage progresses very rapidly and extensively. Effective treatment in this model may indicate the possibility of preventing or treating clinical symptoms in respiratory diseases such as that caused by SARS-CoV-2.

In the described study, the researchers used the LPS-induced ALI model and found that lung damage was significantly inhibited in mice treated with TADIOS. The effects appear to result from the control of excessive production of inflammatory and oxidative molecules such as TNF-alpha, IL-6, IL-1beta and ROS. The potential molecular mechanism underlying TADIOS' anti-inflammatory and anti-oxidative activities is control of the Nrf2-HO-1 pathway. Thus, rather than acting on SARS-CoV-2 itself, TADIOS may instead prevent or inhibit disease progression upon viral infection through a reduction of inflammatory and oxidative response.

https://www.prweb.com/releases/helixmith_announces_the_development_of_botanical_therapeutic_product_for_respiratory_diseases_tadios/prweb17651354.htm